Relationship between in-stent restenosis following carotid artery stenting and platelet reactivity to clopidogrel

Min-Yong Kwon1, Sang Hyo Lee2, Yongjae Lee2

  • 1Department of Neurosurgery, Keimyung University Dongsan Hospital, Daegu, Republic of Korea.

Insights

High platelet reactivity, indicated by elevated P2Y12 reaction units (PRU) and low inhibition rate (IR), is linked to in-stent restenosis after carotid artery stenting. This restenosis may increase the risk of stroke.

Area of Science:

  • Cardiovascular Medicine
  • Interventional Cardiology
  • Pharmacology

Background:

  • Carotid artery stenting (CAS) is a procedure to treat extracranial carotid stenosis.
  • In-stent restenosis (ISR) is a potential complication following CAS.
  • Platelet reactivity to antiplatelet drugs like clopidogrel can influence outcomes after stenting.

Purpose of the Study:

  • To investigate the association between platelet clopidogrel reactivity and the development of in-stent restenosis (ISR) after CAS.
  • To determine the predictive value of P2Y12 reaction units (PRU) and inhibition rate (IR) for ISR.

Main Methods:

  • Retrospective analysis of 171 patients undergoing CAS.
  • Measurement of clopidogrel resistance using PRU and IR before CAS.
  • Classification of ISR severity (R1-R3) using CT angiography at 24-30 months.
  • Receiver operating characteristic (ROC) curve analysis to identify optimal cut-off values for PRU and IR.

Main Results:

  • 19.3% of patients developed moderate to severe ISR (R3).
  • Significantly higher PRU (247.5±55.0) and lower IR (10.3±13.4%) were observed in patients with R3 ISR compared to those with R1+R2 (P<0.001).
  • Optimal cut-off values were PRU ≥220 and IR ≤14.5%, which were significant predictors of ISR R3.

Conclusions:

  • Elevated PRU (≥220) and low IR (≤14.5%) are associated with severe ISR (R3) after CAS.
  • ISR R3 was independently linked to ipsilateral ischemic stroke post-CAS.
  • Monitoring platelet reactivity may help identify patients at higher risk for ISR and subsequent stroke.
Abstract

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
522
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
6.1K